The Kosichenko Oncology Barrier Index (K-OBI): An Evidence-Informed Esthetic Decision-Support Framework for Skin Barrier Screening During Active Cancer Treatment

The Kosichenko Oncology Barrier Index (K-OBI) is an authored, evidence-informed, non-diagnostic esthetic screening and decision-support framework for licensed estheticians working with clients during active or recent cancer treatment. It combines a mandatory Safety Stop screen with five weighted domains: oncology treatment context, client-reported skin comfort, visible barrier findings, home-care and external triggers, and esthetic safety modifiers. The provisional 0–100 caution score routes care toward progressively conservative protocols or Safety Hold. K-OBI does not diagnose disease, grade treatment toxicity, recommend cancer treatment, or replace oncology or dermatology evaluation. Its score weights, thresholds, and protocol pathways require prospective validation.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-09-11
DOI
https://doi.org/10.5281/zenodo.22714342
Primary Topic
Nonmelanoma Skin Cancer Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
preprint

The Kosichenko Oncology Barrier Index (K-OBI): An Evidence-Informed Esthetic Decision-Support Framework for Skin Barrier Screening During Active Cancer Treatment

Anna Kosichenko
Zenodo (CERN European Organization for Nuclear Research)
Nonmelanoma Skin Cancer Studies
preprint

The Kosichenko Oncology Barrier Index (K-OBI): An Evidence-Informed Esthetic Decision-Support Framework for Skin Barrier Screening During Active Cancer Treatment

Anna Kosichenko
preprint en

Abstract

The Kosichenko Oncology Barrier Index (K-OBI) is an authored, evidence-informed, non-diagnostic esthetic screening and decision-support framework for licensed estheticians working with clients during active or recent cancer treatment. It combines a mandatory Safety Stop screen with five weighted domains: oncology treatment context, client-reported skin comfort, visible barrier findings, home-care and external triggers, and esthetic safety modifiers. The provisional 0–100 caution score routes care toward progressively conservative protocols or Safety Hold. K-OBI does not diagnose disease, grade treatment toxicity, recommend cancer treatment, or replace oncology or dermatology evaluation. Its score weights, thresholds, and protocol pathways require prospective validation.

Zenodo (CERN European Organization for Nuclear Research)
Advanced Dermatology (US)
Good health and well-being
Nonmelanoma Skin Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The Kosichenko Oncology Barrier Index (K-OBI): An Evidence-Informed Esthetic Decision-Support Framework for Skin Barrier Screening During Active Cancer Treatment — Anna Kosichenko · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS